Fig. 2

FRα may represent a new therapeutic target in TNBC. FRα surface expression in TNBC cell lines was measured by flow cytometry. FRα-specific mAb MOv18 was used to measure FRα expression on various ovarian cancer (OC) and breast cancer (BC) cell lines (open empty histogram), compared to a matched isotype antibody control (filled gray histogram)